EVLO Insider Trading
Insider Ownership Percentage: 1.02%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Evelo Biosciences Share Price & Price History
Current Price: $0.00
Price Change: ▼ Price Decrease of -0.0001 (-100.00%)
As of 12/16/2025 01:00 AM ET
Evelo Biosciences Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/8/2023 | Marella Thorell | CFO | Sell | 1,811 | $0.33 | $597.63 | 22,259 |  |
| 11/8/2023 | Mark Bodmer | Insider | Sell | 3,163 | $0.33 | $1,043.79 | 25,732 | |
| 11/8/2023 | Simba Gill | CEO | Sell | 172 | $0.33 | $56.76 | 17,758 | |
| 9/28/2023 | Simba Gill | CEO | Sell | 1,996 | $3.94 | $7,864.24 | 16,758 | |
| 8/8/2023 | Marella Thorell | CFO | Sell | 2,004 | $9.51 | $19,058.04 | 9,069 | |
| 8/8/2023 | Mark Bodmer | Insider | Sell | 3,128 | $9.51 | $29,747.28 | 16,624 | |
| 8/8/2023 | Simba Gill | CEO | Sell | 342 | $9.51 | $3,252.42 | 3,754 | |
| 7/11/2023 | Ventures Fund Iv Gene Flagship | Major Shareholder | Buy | 5,411,255 | $2.31 | $12,499,999.05 | 3,931,685 | |
| 5/23/2023 | Mark Bodmer | Insider | Sell | 1,128 | $2.80 | $3,158.40 | 13,127 | |
| 5/8/2023 | Duncan Mchale | Insider | Sell | 3,336 | $2.60 | $8,673.60 | 4,875 | |
| 5/8/2023 | Marella Thorell | CFO | Sell | 1,926 | $2.60 | $5,007.60 | 4,573 | |
| 5/8/2023 | Simba Gill | CEO | Sell | 176 | $2.60 | $457.60 | 2,925 | |
| 1/23/2023 | Stephen J Carriere | Insider | Sell | 7 | $21.20 | $148.40 | 10 | |
Evelo Biosciences Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 1/1/2024 | Vanguard Group Inc. | 357,711 | $1.40M | 0.0% | +129.5% | 1.885% |  |
| 11/13/2023 | FMR LLC | 2,446,390 | $9.59M | 0.0% | +1,835.1% | 12.923% | |
| 11/7/2023 | Barclays PLC | 11,755 | $46K | 0.0% | -87.4% | 0.062% | |
| 8/9/2023 | Mayo Clinic | 22,577 | $73K | 0.1% | -95.3% | 0.403% | |
| 8/4/2023 | Alphabet Inc. | 53,024 | $0.17M | 0.0% | -95.0% | 0.947% | |
| 7/26/2023 | State of Michigan Retirement System | 203,536 | $0.66M | 0.0% | -95.0% | 3.635% | |
| 2/14/2023 | 683 Capital Management LLC | 90,291 | $0.15M | 0.0% | N/A | 0.084% | |
| 2/9/2023 | Mayo Clinic | 479,242 | $0.77M | 0.4% | N/A | 0.444% | |
| 1/26/2023 | Mayo Clinic | 479,242 | $0.77M | 3.9% | N/A | 0.444% | |
| 11/16/2022 | Alphabet Inc. | 1,060,495 | $2.22M | 0.1% | N/A | 0.982% | |
| 11/14/2022 | Ergoteles LLC | 27,429 | $57K | 0.0% | -91.0% | 0.025% | |
| 8/16/2022 | CVI Holdings LLC | 2,054,794 | $4.34M | 0.3% | N/A | 3.829% | |
| 8/15/2022 | Flagship Pioneering Inc. | 50,427,328 | $106.40M | 4.0% | +119.0% | 93.976% | |
| 8/12/2022 | FMR LLC | 16,185,709 | $34.15M | 0.0% | +101.2% | 30.163% | |
| 8/8/2022 | State of Michigan Retirement System | 4,070,728 | $8.59M | 0.1% | +270.1% | 7.586% | |
| 8/5/2022 | abrdn plc | 342,465 | $0.72M | 0.0% | N/A | 0.638% | |
| 8/3/2022 | AE Wealth Management LLC | 56,029 | $0.12M | 0.0% | +78.2% | 0.104% | |
| 5/12/2022 | Group One Trading L.P. | 452,939 | $1.54M | 0.0% | +93.4% | 0.844% | |
| 5/11/2022 | GSA Capital Partners LLP | 72,871 | $0.25M | 0.0% | N/A | 0.136% | |
| 4/20/2022 | Belvedere Trading LLC | 172,792 | $0.40M | 0.0% | -28.3% | 0.322% | |
| 4/18/2022 | AE Wealth Management LLC | 31,437 | $0.11M | 0.0% | +61.0% | 0.059% | |
| 2/14/2022 | Virtus ETF Advisers LLC | 22,257 | $0.14M | 0.1% | +71.1% | 0.042% | |
| 2/14/2022 | Credit Suisse AG | 3,566,487 | $21.65M | 0.0% | +7.7% | 6.671% | |
| 2/11/2022 | Alberta Investment Management Corp | 40,000 | $0.24M | 0.0% | N/A | 0.075% | |
| 2/8/2022 | ProShare Advisors LLC | 14,162 | $86K | 0.0% | N/A | 0.026% | |
| 2/8/2022 | Northern Trust Corp | 300,436 | $1.82M | 0.0% | +0.8% | 0.562% | |
| 2/3/2022 | Larson Financial Group LLC | 5,879 | $36K | 0.0% | -80.2% | 0.011% | |
| 2/2/2022 | New York State Common Retirement Fund | 15,765 | $96K | 0.0% | +57.8% | 0.029% | |
| 1/25/2022 | Belvedere Trading LLC | 241,137 | $1.18M | 0.1% | +75.1% | 0.451% | |
| 1/20/2022 | AE Wealth Management LLC | 19,528 | $0.12M | 0.0% | +21.5% | 0.037% | |
| 11/16/2021 | Two Sigma Advisers LP | 140,600 | $0.99M | 0.0% | +16.7% | 0.263% | |
| 11/15/2021 | Marshall Wace LLP | 38,807 | $0.27M | 0.0% | -38.0% | 0.073% | |
| 11/15/2021 | GSA Capital Partners LLP | 11,624 | $82K | 0.0% | N/A | 0.022% | |
| 11/12/2021 | The Manufacturers Life Insurance Company | 10,483 | $74K | 0.0% | -43.5% | 0.020% | |
| 11/12/2021 | Credit Suisse AG | 3,310,911 | $23.31M | 0.0% | +7.0% | 6.193% | |
| 11/12/2021 | Geode Capital Management LLC | 520,717 | $3.67M | 0.0% | +10.3% | 0.974% | |
| 11/10/2021 | Goldman Sachs Group Inc. | 38,492 | $0.27M | 0.0% | +43.7% | 0.072% | |
| 11/10/2021 | Citigroup Inc. | 5,742 | $40K | 0.0% | +297.6% | 0.011% | |
| 11/9/2021 | Barclays PLC | 12,412 | $87K | 0.0% | +223.0% | 0.023% | |
| 11/9/2021 | BlackRock Inc. | 1,840,250 | $12.95M | 0.0% | -0.2% | 3.442% | |
| 11/8/2021 | State Board of Administration of Florida Retirement System | 10,241 | $72K | 0.0% | N/A | 0.019% | |
| 11/8/2021 | Meeder Asset Management Inc. | 8,858 | $61K | 0.0% | +82.4% | 0.017% | |
| 11/4/2021 | Deutsche Bank AG | 36,952 | $0.26M | 0.0% | +81.8% | 0.069% | |
| 11/4/2021 | Larson Financial Group LLC | 29,705 | $0.21M | 0.0% | -5.3% | 0.056% | |
| 11/2/2021 | New York State Common Retirement Fund | 9,988 | $70K | 0.0% | -63.4% | 0.019% | |
| 11/1/2021 | AE Wealth Management LLC | 16,077 | $0.11M | 0.0% | +14.1% | 0.030% | |
| 11/1/2021 | SG Americas Securities LLC | 10,454 | $74K | 0.0% | N/A | 0.020% | |
| 9/3/2021 | Parametric Portfolio Associates LLC | 22,216 | $0.31M | 0.0% | -21.3% | 0.042% | |
Data available starting January 2016
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More on Evelo Biosciences
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
1,083 shs
Average Volume
9,225 shs
Market Capitalization
$2 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.68
